<DOC>
	<DOCNO>NCT01919944</DOCNO>
	<brief_summary>The purpose study test whether VLY-686 prevent reduce itch dermatological reaction observe healthy volunteer inject Substance P comparison placebo .</brief_summary>
	<brief_title>Study Itch Control VLY-686 Healthy Volunteers After Intradermal Injections Substance P</brief_title>
	<detailed_description>This double-blind , randomize , 4-way crossover , pharmacokinetic pharmacodynamic ( PK/PD ) study compare cutaneous vasoreactive intensity intradermal injection Substance P healthy volunteer receive oral dos 20 mg , 50 mg 100 mg VLY-686 matching placebo . Twelve healthy male subject satisfy selection criterion study enrol . Each subject participate screening period ( 21 day prior dose ) , four one-day treatment period separate 7 ( ±2 day ) day washout period , end-of-study evaluation prior discharge study . This protocol also include option subject administer daily dos study medication Periods 3 4 . The treatment period randomize sequence consist 1 ) 20 mg VLY-686 , 2 ) 50 mg VLY-686 , 100 mg VLY-686 4 ) placebo . In study period , Substance P inject 5 time : pre-dose ( night ) , 2 , 4 , 8 12 hour ( ± 10 minute ) study medication administration . A dose 100 μL 2.5 nmol/mL sterile solution Substance P inject time . Overall , subject administer 1.25 nmol Substance P around 24 hour ( 5 dos ) . Substance P injection give volar forearm , alternate right left avoid injection area adjacent area previously inject . The subject 's forearm cover injection avoid potential bias score Verbal Rating Scale ( VRS ) Visual Analog Scale ( VAS ) . Additionally , blood sample VLY-686 pharmacokinetic ( PK ) analysis collected period pre-dose , 1 , 3 , 6 , 10 , 24 hour study medication administration .</detailed_description>
	<mesh_term>Pruritus</mesh_term>
	<mesh_term>Substance P</mesh_term>
	<mesh_term>Neurokinin A</mesh_term>
	<criteria>Males 18 45 year age , inclusive ; Nonsmokers , per medical history , exsmokers period ≥1 year ; Subjects Body Mass Index ( BMI ) ≥18.5 ≤30 kg/m2 ( BMI = weight ( kg ) / [ height ( ) ] 2 ) ; Vital sign ( sit position 3 minute rest ) within range show ( inclusive ) : Body temperature 35.437.8 °C ; Systolic blood pressure 91130 mmHg ; Diastolic blood pressure 5190 mmHg ; Pulse rate 50100 bpm ; Respiratory rate 1020 breath per minute ; Ability acceptance provide write informed consent ; Willing able comply study requirement restriction ; Subjects must good health determine past medical history , physical examination , electrocardiogram , clinical laboratory test urinalysis . Past present history atopy ( atopic dermatitis problem , urticaria , asthma allergic rhinitis ) ascertain intolerance histamine ; Past present skin disease ; Lesions skin change forearm month prior Screening Visit ; History neurological disease ; Past present painrelated disease cluster headache , migraine , back pain ; Treatment topical cream ointment include cosmetic apply forearm 10 day prior screen visit ; Participation evaluation investigational product 3 month study , calculate first day month follow last visit previous study ; Exposure ( within 2 week Baseline Visit ) prescription medication overthecounter medication include dietary supplement and/or herbal remedy , except list Section 8.2 ; Exposure ( within 4 week Screening Visit ) antihistamine , anxiolytic , antidepressant , pain killer include triptanes , neuroleptic , sleep medication ; Treatment medication know cause major organ system toxicity ( e.g. , chloramphenicol tamoxifen ) 60 day precede Screening Visit ; Administration medication contain corticosteroid adrenocorticotropic hormone three month prior Screening Visit ; Electrocardiogram reading consider outside normal limit investigator ( e.g . abnormally prolonged QTc correct Fridericia 's method &gt; 450 msec male , ECG trace ) . The following conduction abnormality may confound QTc analysis avoid possible : PR &gt; 220 msec , 2nd 3rd degree AV block , intraventricular conduction delay QRS &gt; 120 msec , leave branch bundle block , right branch bundle block WolffParkinsonWhite syndrome ; Blood donation last 3 month donation least 1500 mL blood ( include study ) within last year ; History liver disease and/or positive one follow serological result : A positive hepatitis C antibody test ( antiHCV ) ; A positive hepatitis B surface antigen ( HBsAg ) ; A positive HIV test result ; Not willing sign inform consent able understand completely study objective risk ; Clinically relevant abnormality clinical lab physical assessment perform screen visit ; Lack sensitivity Substance P histamine sensitivity saline Screening Visit ; Any sound medical reason determine clinical Investigator . Drug , alcohol , caffeine , tobacco : history drug , alcohol ( &gt; 2 drinks/day male , define accord USDA Dietary Guidelines 2010 ) , caffeine ( &gt; 5 cup coffee/tea/day ) , smoker ; Diet : abnormal diet ( &lt; 1600 &gt; 3500 calories/day ) substantial change eat habit 4 week study ; vegetarian .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>itch</keyword>
</DOC>